Abstract：【Objective】To investigate the effects of valsartan combined with calcium dobesilate on renal function and renal artery hemodynamics in patients with diabetic nephropathy (DN). 【Methods】A total of 126 diabetic nephropathy patients were randomly divided into two groups with 62 cases each. All patients received routine treatment for diabetes mellitus to control blood glucose after admission. On this basis, the control group (Group B) was treated with valsartan, while the observation group (Group A) was treated with valsartan combined with calcium dobesilate. The course of treatment was 3 months.The clinical efficacy, renal function and renal artery hemodynamics were compared between the two groups. 【Results】After treatment, the total effective rate in Group A was 93.6%, which was significantly higher than 80.9% in Group B (P<0.05). There was no significant difference in the indexes between the two groups before treatment (P>0.05). After treatment, UAER,SCr,BUN and Cys-C of the two groups were significantly lower than those before treatment, and Group A was significantly lower than that of Group B (P<0.05). The systolic maximum flow velocity (Vs max) and the diastolic minimum flow velocity (Vd min) of the renal artery hemodynamic parameters in both groups were higher than those before treatment, and the pulsatility index (PI) and resistance index (RI) were lower than before treatment (P<0.05). Those observations of Group A were better than those of Group B (P<0.05).The incidence of adverse reactions in Group A was 15.8% (10/63), which was significantly lower than that in Group B (30.1%, 19/63) (P<0.05). 【Conclusion】Valsartan combined with calcium dobesilate has better clinical effects on renal function and renal artery hemodynamics in patients with DN, which is worthy of clinical application.
于丽娜, 杨媛媛, 李杭键. 缬沙坦联合羟苯磺酸钙对糖尿病肾病患者肾功能和肾动脉血流动力学的影响[J]. 医学临床研究, 2019, 36(3): 483-485.
YU Li-lao, YANG Yan-yan, LI Hang-jing. Effect of Valsartan Combined with Calcium Dobesilate on Renal Function and Renal Artery Hemodynamics in Patients with Diabetic Nephropathy. JOURNAL OF CLINICAL RESEARCH, 2019, 36(3): 483-485.
[1] 安玉,刘志红.糖尿病肾病病理改变与预后的关系[J].肾脏病与透析肾移植杂志,2013,22(4):368-372. [2] Wang C,Min C,Rong X,et al.Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy [J].DiscovMed,2015,20(108):67-77. [3] 郭海丽.前列地尔联合缬沙坦治疗早期糖尿病肾病临床分析[J].心理医生,2016,22(21):119-120. [4] 李智峰.缬沙坦联合贝那普利治疗糖尿病肾病的临床研究[J].北方药学,2016,13(7):134-135. [5] Fernandez-Fernandez B,Ortiz A,Gomez-Guerrero C,etal. Juxtaglomerular apparatus hyperplasia under dualangiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis[J]. BMC Nephrol,2012,13(1):21. [6] 蔡永红.前列地尔联合缬沙坦治疗老年早期糖尿病肾病的临床观察[J].中国处方药,2016,14(6):63-64. [7] 曾丽娟,黄昭瑄,栾丽丽.羟苯磺酸钙联合缬沙坦治疗早期糖尿病肾病的疗效及其对患者血清ET、CysC水平的影响[J]. 海南医学,201829(8):1064-1066. [8] 侯敬.羟苯磺酸钙联合厄贝沙坦治疗早期糖尿病肾病对蛋白尿、血清炎症介质含量的影响[J].海南医学院学报,2016,22(18):2181-2184.
2019, Vol. 36 
